FAS Wealth Partners’s Myriad Genetics MYGN Stock Holding History

FAS Wealth Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-11,257	Closed	-$385K	–	96
2014 Q1	$385K	Sell	11,257 -9,000	-44%	-$279K	0.26%	43
2013 Q4	$425K	Buy	+20,257	New	+$512K	0.25%	36

Other funds holding MYGN

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Tiger Global Management New York $24B AUM 39.59% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FAS Wealth Partners's MYGN Position: Q2 2014 in Review

FAS Wealth Partners sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 11,257 shares — an estimated $385K sold.

FAS Wealth Partners first reported a position in MYGN in Q4 2013 and held it in 2 quarters. The position peaked at $425K in Q4 2013. 284 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

FAS Wealth Partners reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
FAS Wealth Partners sold 11,257 Myriad Genetics shares in Q2 2014, an estimated $385K.
FAS Wealth Partners first reported a position in Myriad Genetics in Q4 2013 and held it in 2 quarters.
FAS Wealth Partners's Myriad Genetics position peaked at $425K in Q4 2013.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on FAS Wealth Partners's 13F filing for Q2 2014, filed 16 Jul 2014.